Citations

Clear

511 citation(s) found for "Seth, N".

Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy
Fazili, Adnan , Jazayeri, Seyed Behzad , Wen, Lexiaochuan , Durant, Adri , Prunty, Megan , Tyson, Mark D. , Grass, G. Daniel , Xu, Hongzhi, Gilbert, Scott M. , Sexton, Wade J. , Zemp, Logan , Pessoa, Rodrigo Rodrigues, Poch, Michael , Durant, Adri M , Li, Roger , Rose, Kyle , Guske, Christopher W. , Bukavina, Laura , Spiess, Philippe E. , Lerner, Seth P. , Li, Roger

Mayo Clinic

BJU International | September 11, 2025 | Volume: 137 | Issue: 1 | Pages: 181-188

10.1111/bju.16895 | PMID 40932312 Get It

Objectives To compare survival and oncological outcomes of cisplatin‐ineligible patients (Cis‐I) and cisplatin‐eligible (Cis‐E) patients with muscle‐invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard‐of‐care for Cis‐I patients with MIBC. Patients and Methods Data from patients with clinical (c)T2–4cN0–1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence‐free and event‐free survival were described using the Kaplan–Meier method and tested using the log‐rank test. For context, we compared survival outcomes against those in Cis‐E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)‐8710 trial. Results Overall, 379 Cis‐I and 125 Cis‐E patients with cT2–4cN0–1M0 MIBC who underwent IRC were included. Cis‐I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis‐E group. Overall, 83.3% of Cis‐I and 79.2% of Cis‐E patients died during follow‐up. The median event‐free and overall survival were 12.1 and 14.5 months for the Cis‐I group and 28.8 and 60.1 months for the Cis‐E group ( P < 0.001). [Correction added on 10 October 2025, after first online publication: The preceding sentence has been revised in this version.] Limitations include retrospective comparison of contemporary multi‐institutional data with that of a randomised control trial. Conclusions The Cis‐I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1–17.9) months, mostly due to non‐cancer‐related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis‐I patients with MIBC.
Human‐Centered Design to Tailor Telehealth Cardiac Rehabilitation to Diverse Populations: The MCNAIR Study
Oanesa, Rae Denise , Atluri, Namratha , Boyd, Alisa, Khoury, Shireen , Легеза, В. И. , Merritt, J. Greg , McNair, Patricia , Mishra, Sonali R. , Ramsis, Mattheus , Spaulding, Erin M. , Nallamothu, Brahmajee K. , Khoury, Shireen R , Brewer, LaPrincess C , Forman, Daniel Edward , Golbus, Jessica R , Martin, Seth S , Nallamothu, Brahmajee K , Beatty, Alexis L , Boyd, Alisa, Legeza, Vanessa, McNair, Patricia , Brewer, LaPrincess C. , Forman, Daniel E. , Martin, Seth S. , Beatty, Alexis L.

Mayo Clinic

Journal of the American Heart Association | August 23, 2025 | Volume: 14 | Issue: 17 | Pages: No page available

10.1161/jaha.124.040711 | PMID 40847504 Get It

Background Although telehealth cardiac rehabilitation (CR) may improve access, there are concerns about its long‐term effectiveness and impact on equity as compared with in‐person CR. Our objective was to tailor a patient‐centered telehealth CR program for diverse populations. Methods CR patients and caregivers were recruited between January and September 2023 from 4 US academic medical centers. Participants engaged in human‐centered design sessions to iteratively refine a telehealth CR program. Sessions had planned topics, but there was variation across sites to account for site‐specific needs and participant feedback. Sessions were qualitatively analyzed using rapid template analysis with preselected behavioral science constructs and other emergent codes. Results The study included 21 participants (71% aged ≥60 years, 48% women, 62% non‐Hispanic White individuals; 90% CR patients, 10% CR caregivers). Participants thought that telehealth CR could be helpful for personalized support at home and convenience but recognized that technology is not always easy to use. Some expressed concerns about the safety of telehealth CR, especially at the beginning, and desired monitoring through a mobile device or video observation of exercise. Safety protocols and technology training were developed, which addressed concerns about telehealth CR. Opportunities for social support with telehealth CR were also desired. From these findings, an implementation toolkit was developed, including a graphic program description, safety plan, home exercise plan for during and after CR, and scripts for technology training and individual and group telehealth visits. Conclusions A patient‐centered telehealth CR program and implementation toolkit were systematically tailored to address the needs of diverse populations.
DNA Immunotherapy ( INO ‐3107) Results in Long‐Term Surgery Reduction in RRP
Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Pransky, Seth M. , Welsh, Christopher, Slog, Stefani A., Gillespie, Elisabeth, Dallas, Michael, Morrow, Matthew P. , Skolnik, Jeffrey , Best, Simon R , Lott, David G , Mau, Ted , Paniello, Randal C , Slog, Stefani A , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Welsh, Christopher, Dallas, Michael J.

Mayo Clinic

The Laryngoscope | August 9, 2025 | Volume: 135 | Issue: 11 | Pages: 4287-4295

10.1002/lary.32416 | PMID 40781903 Get It

ABSTRACT Objective To evaluate the long‐term safety and clinical effect of INO‐3107 immunotherapy in adults with recurrent respiratory papillomatosis (RRP). Methods RRP‐002 was a retrospective, observational extension study that followed patients enrolled in the 52‐week RRP‐001 study. Patients with moderate to severe juvenile or adult‐onset RRP who had undergone ≥ 2 surgical interventions in the year preceding dosing were eligible for enrollment in RRP‐001. Participants underwent surgical debulking within 14 days prior to initial dosing and then received INO‐3107 on Day 0, Weeks 3, 6, and 9. Efficacy assessments during RRP‐002 follow‐up were the frequency of surgical interventions and alternative medication use. The safety evaluation included reported serious adverse events (SAEs). Results Twenty‐eight (28) of 32 participants from the 52‐week RRP‐001 study were enrolled in RRP‐002. The median follow‐up time for RRP‐002 was 1.8 years (range: 1.2–2.4 years) for a total median assessment time of 2.8 years (range: 1.0–3.5 years). There were no SAEs or long‐term safety concerns identified. The mean number of surgeries was reduced from 4.1 in the pre‐treatment period to 1.7 in the first year post‐INO‐3107 treatment (Year 1) to 0.9 in the second year (Year 2). The complete response rate (0 surgeries per year) increased from 28% (9/32) in Year 1 to 50% (14/28) in Year 2. Conclusion INO‐3107 is well tolerated and provides a continued clinical effect against HPV‐6 and 11 RRP that results in further reduction of the surgical burden observed in Year 1. These data support the role of INO‐3107 immunotherapy for adult patients with RRP. Level of Evidence: III.
Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Awadallah, Andrew S. , Khalil, Yousuf H. , Bowen, Andrew J. , Ali, Hawa M. , Ring, Sydney , McCalla, Monet, Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Ekbom, Dale , Bowen, Andrew Jay , Awadallah, Andrew , Francis, David O , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | July 29, 2025 | Volume: 135 | Issue: 12 | Pages: 4767-4773

10.1002/lary.32464 | PMID 40726462 Get It

ABSTRACT Background Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence 4.
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
Chan, Emily , Pugh, Stephanie L. , Simko, Jeffry, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean‐Paul, Pisansky, Thomas M. , Zeitzer, Kenneth L. , Gore, Elizabeth , Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, L.S., Kuettel, Michael, DeMora, Luda, Dess, Robert T , Bahary, Jean-Paul , Efstathiou, Jason A. , Rosenthal, Seth A. , DeMora, Luda, Sandler, Howard M.

Mayo Clinic

The Prostate | July 21, 2025 | Volume: 85 | Issue: 14 | Pages: 1315-1322

10.1002/pros.70018 | PMID 40686005 Get It

ABSTRACTBackgroundWe aim to evaluate whether increased lymph node yield at prostatectomy (RP) is associated with improved outcomes in NRG/RTOG 9601, a randomized clinical trial of men who underwent either radiation (RT) alone or RT + bicalutamide for PSA elevation following RP for pT2/T3 prostate cancer.MethodsWe reviewed available pathology reports for patients in NRG/RTOG 9601 to determine the nodal count at RP. Cox proportional hazards models were used to assess effect of lymph nodes yield, arm (RT alone or RT + bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease‐specific survival.ResultsOf 760 patients, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range: 0–33, IQR: 3–9). There were no significant differences between arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm. There was no significant association between total lymph nodes and overall or disease‐specific survival with both arms combined and when adjusting for arm. Notably, interaction analysis revealed that in seminal vesicle invasion, there was a significant association between lymph node yield and OS and DSS (HR = 0.91, 95% CI: 0.83–0.99, p = 0.034; HR = 0.87, 95% CI: 0.77–0.99, p = 0.029, respectively).ConclusionsAlthough lymph node yield in NRG/RTOG 9601 did not show association with adverse outcomes in the entire cohort or either arm alone, there was significant association between lymph node yield and adverse outcomes when seminal vesicle invasion was present. The therapeutic benefit of extensive lymph node dissection remains uncertain but could be more relevant in higher risk patients.
Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Su, David , Brown, Leanne , Bansal, Varun , Bakkila, Baylee , Turaga, Kiran K. , Gunderson, Craig G. , Bergsland, Emily K. , Metz, David C. , Kunz, Pamela L. , Gangi, Alexandra , Ly, Quan P. , Fackche, Nadege , Chan, Carlos H.F. , Sundar, Raghav , Hoehn, Richard S. , Dillon, Joseph S. , Su, David G , Brown, Leanne M , Bansal, Varun V , Turaga, Kiran K , Chan, Carlos H F , Dillon, Joseph S , Hoehn, Richard , Concors, Seth Jason , Strosberg, Jonathan , Hálfdánarson, Þorvarður R. , Kunstman, John W. , Olecki, Elizabeth Josephine

Mayo Clinic

Cancer | June 25, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35871 | PMID 40558053 Get It

AbstractNeuroendocrine neoplasms (NENs) with peritoneal metastases (PM) represent a complex clinical challenge because of low incidence and heterogeneous phenotypes. This commentary describes the results of a national consensus aimed at addressing clinical management of patients with NENs and PM. An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique, which encompassed two rounds of voting. The levels of agreement for various pathway blocks were assessed, and key systemic therapy concepts were summarized by content experts. Supporting evidence was evaluated via a rapid literature review. Overall, the level of evidence for the management of PM in this disease was universally low. In total, 107 participants responded in the first round, with 88 of 107 (82%) participating in the second round. Strong consensus (>90%) was achieved in five of seven (71%) and seven of seven (100%) blocks in rounds 1 and 2, respectively. A multidisciplinary approach including psychosocial and wellness assessments received a strong positive recommendation. Management of NENs with PM was organized according to disease grade and symptom profiles. In grade 1 and 2 well‐differentiated NENs, cytoreductive surgery received strong support (>95%) after the management of functional syndromes (if present). For grade 3 well‐differentiated NENs, systemic therapy is the primary recommendation, with surgical resection considered in select cases. Given the limited evidence, the consensus‐driven clinical pathway offers vital clinical guidance for the management of NENs with PM. The need for high‐quality evidence remains critical to the field.
Surgical Treatment and Complications of Lateral Extra‐articular Procedures in the Anterior Cruciate Ligament–Reconstructed Knee: Part II of an International Consensus Statement
Sonnery‐Cottet, Bertrand , Carrozzo, Alessandro , Saithna, Adnan , Vieira, Thaïs Dutra , Musahl, Volker , Helito, Camilo Partezani , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles, Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W., Monaco, Edoardo , Getgood, Alan , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles , Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W.

Mayo Clinic

Arthroscopy | June 20, 2025 | Volume: 41 | Issue: 9 | Pages: 3313-3321

10.1016/j.arthro.2025.06.013 | PMID 40544924 Get It

Purpose To establish international expert consensus on surgical techniques, complications, and rehabilitation protocols for lateral extra‐articular procedures (LEAPs) performed adjunctively with anterior cruciate ligament reconstruction. Methods Fifty‐five knee surgeons from 17 countries on 5 continents completed a 3‐round modified Delphi process. In the final round, 16 statements on LEAP techniques and complications were scored on a 5‐point Likert scale; ≥75% “agree/strongly agree” constituted consensus. When appropriate, strength of recommendation was graded. Statements lacking support were revised until consensus or abandonment. Results Six statements achieved unanimous consensus (100%), 2 had strong consensus (90%‐99.9%), and 3 reached consensus (75%‐89.9%); 4 were removed. Key technical recommendations were as follows: (1) in iliotibial band procedures, the graft strip should pass beneath the lateral collateral ligament; (2) an anatomic technique is mandatory for anterolateral ligament reconstruction; and (3) no single LEAP is clinically superior to another. Unanimous agreement indicated that modern LEAPs do not increase lateral compartment osteoarthritis risk, carry a low complication rate, and do not necessitate changes to rehabilitation or return‐to‐play timelines. Conclusions Consensus defined core surgical principles and confirmed the safety of adding LEAPs to anterior cruciate ligament reconstruction. When an iliotibial band graft is used, it should be routed deep to the lateral collateral ligament and fixed between 0° and 60° of knee flexion under low tension. For anterolateral ligament reconstruction, femoral fixation should be in full extension at a posterior‐proximal point relative to the lateral epicondyle. Although no single LEAP proved superiority, adherence to these principles permits safe, effective surgery without altering standard rehabilitation or return‐to‐sport protocols and without increasing osteoarthritis risk. Level of Evidence Level V, expert opinion.
Indications for Lateral Extra‐articular Procedures in the Anterior Cruciate Ligament–Reconstructed Knee: Part I of an International Consensus Statement
Sonnery‐Cottet, Bertrand , Carrozzo, Alessandro , Saithna, Adnan , Vieira, Thaïs Dutra , Musahl, Volker , Helito, Camilo Partezani , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles, Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W., Sherman, Seth L. , Monaco, Edoardo , Getgood, Alan , Panel, The International Experts, Bedi, Asheesh, Bryant, Dianne, Cavaignac, Etienne, Chahla, Jorge, Claes, Steven, Cordasco, Frank, Daggett, Matt, Devitt, Brian, Feller, Julian, Fink, Christian, Frank, Rachel, Geeslin, Andrew, Grassi, Alberto, Green, Daniel, Guenther, Daniel, Heard, Mark, Herbst, Elmar, Hopper, Graeme, Inderhaug, Eivind, Irrgang, James, Kaeding, Christopher, Kittl, Christopher, Kocher, Mininder, Koga, Hideyuki, Krych, Aaron J., LaPrade, Robert, Levy, Bruce, Litchfield, Robert Bruce, Lording, Tim, Lowe, Walter, MacDonald, Peter, Marx, Robert, Moatshe, Gilbert, Neri, Thomas, Ouanezar, Herve, Padua, Vitor Barion de Castro, Parker, David, Pioger, Charles , Servien, Elvire, Sherman, Seth, Smith, Patrick, Spalding, Tim, Tapasvi, Sachin, Verdonk, Peter, Williams, Andy, Xerogeanes, John, Young, Simon W.

Mayo Clinic

Arthroscopy | June 20, 2025 | Volume: 41 | Issue: 9 | Pages: 3303-3312

10.1016/j.arthro.2025.06.012 | PMID 40544926 Get It

Purpose To define expert consensus on whether and how lateral extra‐articular procedures (LEAPs) should accompany anterior cruciate ligament (ACL) reconstruction to optimize outcomes in ACL‐deficient knees. Methods Fifty‐five knee surgeons from 17 countries on 5 continents completed a 3‐round modified Delphi process. Twenty‐one statements on patient selection for combined ACL reconstruction (ACLR) + LEAPs were graded on 5‐point Likert scales; ≥75% “agree/strongly agree” signified consensus. Strength of recommendation was ranked, and statements failing the threshold were revised or discarded after discussion. Results One statement achieved unanimous agreement (100%): it is strongly recommended to add a LEAP for active patients ≤25 years receiving hamstring‐autograft ACLR to reduce graft failure. Strong consensus (≥90%) supported LEAPs in primary ACLR when grade 3 pivot shift (97.9%), knee hyperextension (97.9%), skeletally immature status (79.5%), revision ACLR (91.5%), return to pivoting sports (93.2%), active patients ≤25 years using nonhamstring grafts (90.7%), grade 3 Lachman test (90%), and when multiple relative risk factors coexist (statement 36, 97.1%). Consensus (75%‐89.9%) favored LEAPs for chronic symptomatic ACL deficiency (86.1%), posterior tibial slope >12° (85.7%), and a history of contralateral ACL injury (88.9%). Eight statements did not reach consensus regarding small‐diameter autografts, female athletes, imaging signs of anterolateral injury (e.g., Segond fracture, lateral femoral‐notch sign), and concomitant meniscal procedures. One statement on LEAPs with primary ACL repair was withdrawn because the project focused on reconstruction. Conclusions International experts strongly recommend adding a LEAP in young active patients undergoing hamstring‐autograft ACLR and in cases of high‐grade rotational or anterior laxity, knee hyperextension, revision surgery, or returning to pivoting sports. Unresolved issues include small graft size, female athletes, imaging findings of rotational instability, and concurrent meniscal procedures, highlighting priorities for future research. Level of Evidence Level V, expert opinion.
Current Perspectives on Mesenchymal Dendritic Cell Neoplasms of Lymphoid Tissue: Insights into Ontogeny, Updates on Classification, and Clinicopathologic Characteristics
Seth, Neha , Abeykoon, Jithma P. , Tessier, Steven , King, Rebecca L. , Ravindran, Aishwarya , Ravindran, Aishwarya , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Cancers | June 19, 2025 | Volume: 17 | Issue: 12 | Pages: 2055

10.3390/cancers17122055 | PMID 40563703 Get It

Mesenchymal dendritic cell neoplasms represent a distinct category of hematologic malignancies that challenge traditional classifications of histiocytic and classical dendritic/Langerhans cell neoplasms. Historically grouped under the broader umbrella of dendritic cell neoplasms, these entities differ significantly in their ontogeny, histopathologic features, molecular alterations, and clinical behavior. They are categorized into three main subtypes including follicular dendritic cell sarcoma, fibroblastic reticular cell tumor, and EBV-positive inflammatory follicular dendritic cell sarcoma/fibroblastic reticular cell tumor. They originate from mesenchymal stromal cells, and genetic alterations activating the NF- κβ pathway are frequent in follicular dendritic cell sarcomas. Immunophenotypic characterization is critical to distinguish these from other hematologic malignancies including histiocytic and classical dendritic/Langerhans cell neoplasms and other solid (non-hematopoietic) cancers. This review recapitulates current knowledge on existing classifications, details their diverse ontogeny from classical dendritic cell neoplasms, and provides insights into their clinicopathologic characteristics to improve diagnostic accuracy. We detail two case studies that demonstrate the challenges involved in the histopathologic diagnosis of these rare tumors, necessitating a comprehensive workup. Integrating developmental biology into practical diagnostic algorithms is essential to improve recognition and classification of these underdiagnosed neoplasms, ultimately guiding timely management.
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
Chawla, Neal Shiv , Attia, Steven , Cranmer, Lee D., Seetharam, ­Mahesh , Bui, Nam Q. , Somaiah, Neeta , Tine, Brian Andrew Van, Chawla, Sant P. , Bui, Nam , Jones, Robin L. , Pollack, Seth M. , Cranmer, Lee D. , Pousa, Antonio Lopez , Burgess, Melissa , Chmielowski, Bartosz , Siontis, Brittany L. , Trent, Jonathan C. , Wilky, Breelyn A , Chugh, Rashmi

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 11506-11506

10.1200/jco.2025.43.16_suppl.11506 Get It

11506 Background: Catequentinib Hydrochloride (AL3818, Anlotinib, Catequentinib) is a novel, orally administered, small molecule tyrosine kinase inhibitor. There remains an unmet need for effective, well tolerated therapies for patients (pts) with advanced/ metastatic leiomyosarcoma (LMS). We performed a randomized, double blind trial of Catequentinib monotherapy versus placebo in advanced/metastatic LMS. Methods: Patients with a diagnosis of LMS requiring third or further line treatment were eligible. Catequentinib was administered in a 21-day cycle with 14 days on and 7 days off regimen. In this double blind phase 3 trial, patients were randomized 2:1 to Catequentinib or placebo, with the option of crossover to Catequentinib after confirmed Progression Disease (PD) on placebo. Progression-free survival (PFS) with Log Rank test was the primary endpoint and the trial was conducted at multiple sites in the US, UK and EU. Results: Total N = 111 patients were enrolled, and N = 110 were treated and evaluated, 74 randomized to Catequentinib (C), and 36 to placebo (P). In arms (C)/(P) median ages were 59.0/60.5 (range: 33-91) years respectively and 59/29 (79.7%/80.6%) were female. Median PFS by Blinded Independent Central Review (BICR) met the primary endpoint at 3.42 months (95% CI: 2.60, 6.83) for (C) and 1.41 months (95% CI: 1.35, 4.86) for (P) with a p-value of 0.0265 and a HR of 0.536 (95% CI: 0.307, 0.936). Median PFS for patients stratified at ≤ 3 prior lines was 4.86 months (95% CI: 2.04, 8.94) for (C) and 1.41 months (95% CI: 1.31, 4.86) for (P) with a p-value of 0.0046 and a HR of 0.386 (95% CI: 0.196, 0.760). The 6-month progression-free rate was 42.37% for (C) and 20.71% for (P). OS was 17.45 months (95% CI: 13.57, 19.32) for (C) and 16.33 months (95% CI: 11.27, NE) for crossover patients in the (P) arm. 30 (40.5%) of patients have experienced grade 3 treatment-related adverse events in the (C) arm compared to 3 (8.3%) of patients in the (P) arm. The most common TEAE for (C) vs (P) were diarrhea (50.0% vs 22.2%), stomatitis (31.1% vs 8.3%), fatigue (64.9% vs 41.7%), and hypertension (47.3% vs 19.4%). Conclusions: This phase 3 trial met the primary PFS endpoint and demonstrates superior PFS for Catequentinib vs placebo in metastatic/advanced LMS. This study confirms the acceptable benefit-risk profile of Catequentinib in LMS. Catequentinib is an effective and well tolerated treatment option for patients with LMS. Clinical trial information: NCT03016819 .